WestGene Biopharma Presents Groundbreaking mRNA Vaccine Data at ESMO 2024

BARCELONA, Spain, Sept. 17, 2024 /PRNewswire/ -- WestGene Biopharma, a leading innovator in mRNA therapeutics, presented the latest clinical data for its EBV-positive tumour mRNA vaccine, WGc-043, during a mini-oral presentation at the European Society for Medical Oncology (ESMO) Congress 2024.

Pioneering Advances in mRNA Therapeutics

WGc-043, the world's first mRNA therapeutic vaccine targeting EBV-positive tumors to achieve IND approval in both China and the US, demonstrated exceptional safety, immunogenicity, and anti-tumor activity in the latest clinical trials. The vaccine is being developed specifically for adult patients with advanced EBV-positive solid tumours and refractory or relapsed EBV-positive lymphomas, diseases for which there are currently no effective, low-toxicity treatment options.

Impressive Clinical Performance Recognized by ESMO

Interim clinical data presented at ESMO 2024 highlighted the vaccine's ability to activate the patient's immune system, leading to the production of cytotoxic T cells, antigen-specific antibodies and memory T cells that target and destroy cancer cells. This novel mechanism offers a promising alternative to conventional CAR-T and monoclonal antibody therapies and also aims to prevent tumor recurrence, providing a triple benefit, particularly for patients with late-stage nasopharyngeal carcinoma and NK/T cell lymphoma.

Innovative Technology and Global Impact

WGc-043 is a testament to WestGene's proprietary mRNA platform, which includes cutting-edge innovations in mRNA sequence design, novel lipid nanoparticle (LNP) delivery systems, and scalable manufacturing processes. The vaccine was developed using WestGene's patented LNP technology, which is recognized for its superior efficacy and safety. This technology has been instrumental in overcoming the challenges associated with mRNA vaccine delivery and has positioned WestGene as a leader in the global mRNA therapeutic

Expanding Horizons in Cancer Treatment

The global market for mRNA cancer vaccines is expected to grow significantly, with estimates ranging from $230 billion to $300 billion by 2035. The success of WGc-043 at ESMO underscores the potential of mRNA technology not only to lead the field, but also to accelerate clinical development and provide safe, effective treatments for late-stage cancer patients.

Looking Ahead

WestGene Biopharma (www.westgenepharma.com) remains committed to advancing its mRNA platform and expanding its pipeline to address unmet medical needs across a range of indications. The company's innovative approach and commitment to collaboration will continue to drive progress in the field of mRNA therapeutics and bring hope to patients worldwide.

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

WestGene Biopharma Presents Groundbreaking mRNA Vaccine Data at ESMO 2024

RIYADH, Saudi Arabia, Oct. 5, 2024 /PRNewswire/ --The Literature, Publishing & Translation Commission, part of the Saudi Ministry of Culture, has revealed that the Riyadh Book Fair 2024 is its largest edition yet, featuring a diverse range of translated international books. With more than 2,000 local, Arab, and international publishers participating, the Fair has strengthened its position as a leading cultural event in the Arab world. This year's edition promotes Saudi Arabia's cultural openness and supports the spread of cross-border knowledge.

The 2024 Fair edition stands out for hosting renowned thinkers, intellectuals, and global figures in literature, art, and knowledge who share their insights and success stories with the public. Among the key speakers are Fareed Zakaria, acclaimed media personality and author; Walter Isaacson, world-renowned biographer; poet and writer Kwame Alexander; and acclaimed novelist Jonathan Franzen. The Fair also features prominent literary and artistic figures from the Middle East.

Dr Mohammed Hasan Alwan, CEO of the Literature, Publishing & Translation Commission, emphasised the significance of the Fair, stating: "The Riyadh International Book Fair is not only one of the most important book fairs in the Arab region but also a premier platform for publishers and authors to expand their reach in the Arab cultural market. This year's edition is especially notable for its focus on cultural diversity and translation, with an exceptional programme featuring some of the world's leading intellectuals."

During his visit, His Excellency Chang Hua, the Chinese Ambassador to Saudi Arabia, expressed admiration for the Saudi public's enthusiasm for reading. CNN's Fareed Zakaria praised the Kingdom's remarkable transformation and its growing global influence.

This year also marks the return of the popular "Riyadh Reads French" initiative, featuring several French publishers. Al-Saeed Ezz, Communication Officer at the French Embassy, noted that this year's programme has expanded to include children's activities and free French language courses in collaboration with the French Cultural Institute, bringing French culture closer to Saudi visitors.

The Riyadh International Book Fair plays a key role in supporting Saudi Vision 2030's cultural goals, contributing to the Kingdom's cultural economy, projected to reach $9.3 billion. Attracting over one million visitors annually, it ranks among the highest-selling book fairs in the Arab world.

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

Riyadh International Book Fair 2024: Expanding Global Dialogue through the Largest Collection of Translated Works